Zelira secures $1 Million At-the-Market Funding Facility
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Zelira Therapeutics Ltd. has secured an At-the-Market funding facility with Securities Vault to support its clinical programs and growth strategy. Zelira retains control over the timing and amount of capital issuances, minimizing dilution for shareholders. The agreement allows for the issuance of shares without shareholder approval, enhancing financial flexibility for the company.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zelira Therapeutics Ltd. on 6ix
In the deck
Earlier from Zelira Therapeutics
- Appendix 4D & FY25 Interim Financial Report
- Zelira receives $1,153,000 R&D Tax Incentive Scheme Refund
- Zeliras HOPE SPV Secures US$681,000 Fourth Funding Tranche
- September 2024 Quarterly Activities Report
- Appendix 4C Cash Flow Report
Later from Zelira Therapeutics
- Publication of ZLT-L-007 IRB Approved Observational Study
- Zelira Therapeutics Secures R&D Loan Facility
- Preliminary Final Report
- Zelira receives $1,070,000 R&D Tax Incentive Scheme Refund
- Transformative US$33M Fundraising into Zeliras HOPE 1 SPV
Follow Zelira Therapeutics into a list and get an email when it puts out news.
Follow Zelira Therapeutics